Analysts Set Enfusion, Inc. (NYSE:ENFN) Target Price at $9.33

Shares of Enfusion, Inc. (NYSE:ENFN) have earned an average rating of “Reduce” from the six analysts that are presently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and one has given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $9.33.

Several research firms recently issued reports on ENFN. The Goldman Sachs Group lowered shares of Enfusion from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $9.00 to $8.00 in a research report on Wednesday, February 28th. Piper Sandler lifted their target price on shares of Enfusion from $9.00 to $10.00 and gave the stock a “neutral” rating in a research note on Wednesday, December 20th. Bank of America lifted their price target on shares of Enfusion from $8.00 to $9.00 and gave the company an “underperform” rating in a research note on Wednesday, March 13th. Finally, JPMorgan Chase & Co. downgraded shares of Enfusion from a “neutral” rating to an “underweight” rating and decreased their price target for the company from $11.00 to $9.00 in a research note on Tuesday, January 30th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in shares of Enfusion by 17.2% in the 3rd quarter. Vanguard Group Inc. now owns 3,487,815 shares of the company’s stock worth $31,286,000 after buying an additional 512,479 shares during the last quarter. Hudson Bay Capital Management LP boosted its stake in shares of Enfusion by 29.7% during the 3rd quarter. Hudson Bay Capital Management LP now owns 460,084 shares of the company’s stock valued at $4,127,000 after purchasing an additional 105,236 shares in the last quarter. Algert Global LLC purchased a new position in Enfusion in the third quarter worth about $139,000. New York State Common Retirement Fund raised its holdings in Enfusion by 17.2% in the third quarter. New York State Common Retirement Fund now owns 1,618,803 shares of the company’s stock worth $14,521,000 after buying an additional 237,841 shares during the last quarter. Finally, Swiss National Bank raised its holdings in shares of Enfusion by 55.7% during the third quarter. Swiss National Bank now owns 49,500 shares of the company’s stock valued at $444,000 after purchasing an additional 17,700 shares during the last quarter. 81.05% of the stock is currently owned by hedge funds and other institutional investors.

Enfusion Trading Up 0.4 %

Shares of ENFN opened at $9.57 on Friday. Enfusion has a 12 month low of $7.37 and a 12 month high of $11.56. The firm’s 50 day moving average is $8.98 and its 200-day moving average is $9.11. The stock has a market capitalization of $1.23 billion, a PE ratio of 119.64, a P/E/G ratio of 2.79 and a beta of 1.00.

Enfusion (NYSE:ENFN) last announced its earnings results on Tuesday, March 12th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). The business had revenue of $46.49 million for the quarter, compared to the consensus estimate of $45.56 million. Enfusion had a return on equity of 10.30% and a net margin of 3.45%. Equities research analysts predict that Enfusion will post 0.07 earnings per share for the current fiscal year.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.